Prospective, non-randomized interventional study evaluating efficacy, safety, refractive accuracy, and stability of WaveLight Plus InnovEyes ray-tracing-guided LASIK in 800 eyes (400 patients) with myopia or myopic astigmatism, including a subgroup of 300 eyes with preoperative cylinder ≥1.50 D, followed for 12 months.
At 12 months, 100% of eyes achieved UDVA ≥20/20 and 68% achieved ≥20/16; 96.5% were within ±0.50 D of target SE; refractive stability was strong with only 0.38% of eyes showing >0.50 D change from 1–12 months. In the high-cylinder subgroup, 91.7% had residual astigmatism ≤0.50 D and 85% of eyes had axis error within ±5°. No eyes lost ≥2 lines of CDVA.
- Non-randomized design with no control arm limits comparative conclusions. - Single-platform study; results may not generalize to other ray-tracing or wavefront-guided systems. - 12-month follow-up may not capture longer-term refractive drift or regression.
Ray-tracing-guided LASIK with WaveLight Plus InnovEyes delivers high predictability and safety for myopia and myopic astigmatism, including eyes with cylinder ≥1.50 D — clinicians can expect precise axis alignment and low residual error with this platform. The mild systematic undercorrection (mean CI ~0.94) is worth monitoring when planning treatments for high astigmats.
Explore related topics
